NO20073760L - Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister - Google Patents

Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister

Info

Publication number
NO20073760L
NO20073760L NO20073760A NO20073760A NO20073760L NO 20073760 L NO20073760 L NO 20073760L NO 20073760 A NO20073760 A NO 20073760A NO 20073760 A NO20073760 A NO 20073760A NO 20073760 L NO20073760 L NO 20073760L
Authority
NO
Norway
Prior art keywords
disorders
tetrazolone
triazolone
alzheimer
disease
Prior art date
Application number
NO20073760A
Other languages
English (en)
Inventor
Xavier Jean Michel Langlois
Jose Ignacio Andres-Gil
Manuel Jesus Alcazar-Vaca
Joaquin Pastor-Fernandez
Wilhelmus Helena I Drinkenburg
Julen Oyarzabal-Santamarina
Juan Antonio Vega-Ramiro
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20073760L publication Critical patent/NO20073760L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører substituerte triazolon-, tetrazolon- og imidazolonderivater i henhold til den generelle formel (I) (I) et farmasøytisk akseptabelt syre- eller baseaddisjonssalt derav, en stereokjemisk isomer form derav, en N-oksidform derav eller et kvaternært ammoniumsalt derav, hvori variablene er definert i krav 1, som har selektiv ?2C-adrenoreseptorantagonistaktivitet. Den vedrører ytterligere deres fremstilling, sammensetninger omfattende dem og deres anvendelse som en medisin. Forbindelsene ifølge oppfinnelsen er nyttige for forebyggingen og/eller behandlingen av sentralnervesystemlidelser, sinnsstemningslidelser, angstlidelser, stressrelaterte lidelser assosiert med depresjon og/eller angst, kognitive lidelser, personlighetslidelser, schizoaffektive lidelser, Parkinsons sykdom, demens av Alzheimer-typen, kroniske smertetilstander, nevrodegenerative sykdommer, avhengighetslidelser, sinnsstemningslidelser og seksuell dysfunksjon. ?? ?? ?? ?? 1
NO20073760A 2004-12-21 2007-07-19 Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister NO20073760L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04106817 2004-12-21
EP05104873 2005-06-03
PCT/EP2005/056951 WO2006067139A1 (en) 2004-12-21 2005-12-20 Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists

Publications (1)

Publication Number Publication Date
NO20073760L true NO20073760L (no) 2007-07-19

Family

ID=36013649

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073760A NO20073760L (no) 2004-12-21 2007-07-19 Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister

Country Status (15)

Country Link
US (1) US20100029620A1 (no)
EP (1) EP1831185A1 (no)
JP (1) JP2008524312A (no)
KR (1) KR20070090941A (no)
AR (1) AR052342A1 (no)
AU (1) AU2005318188A1 (no)
BR (1) BRPI0516380A (no)
CA (1) CA2588028A1 (no)
EA (1) EA011514B1 (no)
IL (1) IL184048A0 (no)
MX (1) MX2007007472A (no)
NO (1) NO20073760L (no)
PA (1) PA8657301A1 (no)
TW (1) TW200635906A (no)
WO (1) WO2006067139A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5650404B2 (ja) 2006-12-28 2015-01-07 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｎ−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
JP5787237B2 (ja) * 2010-10-01 2015-09-30 大正製薬株式会社 １，２，４−トリアゾロン誘導体
FR2976287B1 (fr) 2011-06-09 2013-07-05 Pf Medicament Derives benzoquinolizidines, leur procede de preparation et leurs applications en therapeutique
EP2772482B1 (en) * 2011-10-27 2016-03-09 Taisho Pharmaceutical Co., Ltd. Azole derivative
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
BR112015030824A2 (pt) * 2013-06-11 2017-07-25 Hoffmann La Roche novos derivados de tetrazolona
EP3013342B1 (en) 2013-06-27 2021-04-14 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
EP3484877B1 (de) 2016-07-12 2020-07-01 Bayer CropScience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
JP2021501794A (ja) * 2017-11-06 2021-01-21 エースロット, インコーポレイテッドAcelot, Inc. Ａβ４２オリゴマー形成に関連する疾患の治療のための小分子薬剤、及び関連する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3355457A (en) * 1965-05-21 1967-11-28 American Cyanamid Co Substituted 2-imidazolinones
DE2725148A1 (de) * 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
CA2179640C (en) * 1994-01-24 2005-11-15 Jan Heeres Watersoluble azole antifungals
JPH0899975A (ja) * 1994-08-05 1996-04-16 Nippon Bayeragrochem Kk ５員複素環置換テトラゾリノン誘導体および除草剤
JPH09183770A (ja) * 1995-10-31 1997-07-15 Nippon Bayeragrochem Kk １−アジン−テトラゾリノン類及び除草剤
WO1998025912A1 (en) * 1996-12-13 1998-06-18 E.I. Du Pont De Nemours And Company Herbicidal heterocyclic amides
WO1998051683A1 (en) * 1997-05-15 1998-11-19 E.I. Du Pont De Nemours And Company Herbicidal tetrazolinones
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
JP3837242B2 (ja) * 1998-08-25 2006-10-25 北興化学工業株式会社 トリアゾリノン誘導体および除草剤
AU5301799A (en) * 1998-08-19 2000-03-14 Hokko Chemical Industry Co. Ltd. Triazolinone derivatives and herbicide compositions

Also Published As

Publication number Publication date
TW200635906A (en) 2006-10-16
JP2008524312A (ja) 2008-07-10
IL184048A0 (en) 2007-10-31
AR052342A1 (es) 2007-03-14
MX2007007472A (es) 2007-07-20
CA2588028A1 (en) 2006-06-29
US20100029620A1 (en) 2010-02-04
BRPI0516380A (pt) 2008-09-02
EP1831185A1 (en) 2007-09-12
KR20070090941A (ko) 2007-09-06
WO2006067139A1 (en) 2006-06-29
EA011514B1 (ru) 2009-04-28
AU2005318188A1 (en) 2006-06-29
PA8657301A1 (es) 2007-01-17
EA200701345A1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
NO20073760L (no) Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister
ECSP056192A (es) 3-fluoro-piperidinas como antagonistas de nmda/nr2b
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
NO20091766L (no) Spiro-piperidinderivater
IL198072A0 (en) Substituted pyrazinone derivatives for use as a medicine
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
NO20072972L (no) Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler
NO20052172D0 (no) 4-aminopiperidinderivater, fremgangsmate for deres fremstilling og deres anvendelse som medikamenter
WO2009121155A3 (en) Flavone containing compositions for treating mao associated disorders
NO20055758L (no) Heteroarylsubstituerte imidazolderivater som glutamatreseptorantagonister
WO2007135131A8 (en) Substituted pyrazinone derivatives for use as a medicine
NO20091830L (no) Spiro-piperidinderivater som VIa reseptorantagonister
NO20084819L (no) Substituerte pyrazinonderivater for anvendelse som en medisin
ATE461190T1 (de) Substituierte pyradinon-derivate als alpha2- adrenorezeptor-antagonisten
ATE440826T1 (de) Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
MX2010009820A (es) 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a.
BRPI0512404A (pt) inibidores de mao-b
DE502007006951D1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application